Products for Research Use Only

(±) -BI-D

CAT: 0804-HY-18601-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18601-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(±) -BI-D is a potent ALLINI (allosteric integrase inhibitor) . (±) -BI-D binds integrase at the LEDGF/p75 binding site. (±) -BI-D inhibits HIV-Luc infection in cells (IC50: 0.16 μM in Psip1 knockout E9 mouse embryonic fibroblasts, 2.9 μM in wild-type E9 mouse embryonic fibroblasts) [1][2].
CAS Number
1416258-16-6
UNSPSC
12352005
Target
HIV; HIV Integrase
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/__plusmn__-BI-D.html
Purity
98.06
Solubility
DMSO : ≥ 100 mg/mL
Smiles
OC(C(OC(C)(C)C)C1=C(C(C=CC=C2)=C2N=C1C)C3=CC(CCCO4)=C4C=C3)=O
Molecular Formula
C25H27NO4
Molecular Weight
405.49
References & Citations
[1]Wang H, et al. HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res. 2012 Dec;40 (22) :11518-30.|[2]Fader LD, et al. Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV. ACS Med Chem Lett. 2014 Apr 16;5 (6) :711-6.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported